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Prognostic factors in patients irradiated after incomplete excision
of low-grade cerebral astrocytoma
Jadwiga Nowak-Sadzikowska
I n t r o d u c t i o n. Low grade astrocytomas account for 10-15% of primary adult brain tumours. The management of low-gra-
de cerebral astrocytoma is controversial. Surgery is usually attempted and either biopsy or subtotal or total excision is under-
taken. Complete surgical resection is potentially curative. After subtotal resection of the tumour, different polices are being pur-
sued: planned immediate postoperative radiotherapy or retreatment by surgery or radiotherapy on progression of the disease.
M a t e r i a l  a n d  m e t h o d. One hundred and nineteen patients with incompletely excised low-grade astrocytomas (WHO gra-
de II) irradiated between 1976 and 1993 at the Department of Radiation Oncology of Maria Sk∏odowska-Curie Memorial Can-
ser Center in Kraków, were retrospectively reviewed. Fifty astrocytomas were classified as fibrillary, twenty two as protoplasmic
and thirty seven as gemistocytic. All patients were treated with megavoltage gamma rays (60Co). The total dose ranged from
50 to 64 Gy (mean: 59.23 Gy) delivered with daily fractions of 1.6-2.5 Gy. The three-field technique (parallel-opposed late-
ral portals with wedges and anterior portal), or anterior and lateral portals with wedges were used. The treatment volume co-
vered the tumour residual with a margin of (1-2 cm). Factors analysed for prognostic significance included: age, gender, per-
formance status, neurological function, length and nature of symptoms, tumour localisation, stage, histology, extend of sur-
gery, interval from operation to radiotherapy and total dose.
R e s u l t s. Toxicity was acceptable. The 5-year and 10-year overall actuarial survival rates were 39% and 24%, respectively.
The following characteristics were associated with improved patient survival by univariate analysis: age (30, very good neuro-
logical function before radiotherapy, fibrillary or protoplasmic histology, female gender (p(0.05). Multivariate analysis showed
that only age was correlated with survival time. Patients under 30 years of age carried the best prognosis.
C o n c l u s i o n. 1. Combined surgery and postoperative radiotherapy in patients with incompletely excised low-grade cerebral
astrocytoma results in obtaining 5-year and 10-year overall actuarial survival rates in 39% and 24% of cases, respectively.
2. The tolerance of radical radiotherapy with total doses of 50-64 Gy delivered with classical factions, covering the tumour re-
sidual with a margin, is good. 3. Age is the most significant variable determining the survival of patients with incompletely exci-
sed low-grade astrocytoma.
Czynniki prognostyczne u chorych na wysokozró˝nicowane gwiaêdziaki mózgu,
napromienianych po zabiegach nieradykalnych
W s t ´ p. Wysokozró˝nicowane gwiaêdziaki stanowià 10-15% guzów mózgu u doros∏ych. Post´powanie z chorymi na wysoko-
zró˝nicowane gwiaêdziaki mózgu jest przedmiotem kontrowersji. Podstawowà metodà leczenia tych nowotworów jest neuro-
chirurgia. W przypadku radykalnego usuni´cia guza adiuwantowe napromienianie nie jest zalecane. Po nieradykalnym lecze-
niu operacyjnym stosowane sà ró˝ne sposoby post´powania: planowane uzupe∏niajàce napromienianie lub odraczanie lecze-
nia chirurgicznego czy napromienianiem do wystàpienia progresji guza.
M e t o d y k a  i m a t e r i a ∏. Przeprowadzono retrospektywnà analiz´ grupy 119 chorych na wysokozró˝nicowane gwiaê-
dziaki mózgu, napromienianych po zabiegach nieradykalnych w Centrum Onkologii w Krakowie w latach 1976-1993. Do wy-
sokozró˝nicowanych gwiaêdziaków (WHO II°) zaliczono nast´pujàce postacie histologiczne: gwiaêdziak w∏ókienkowy – 50
chorych, gwiaêdziak protoplazmatyczny – 22 chorych, gwiaêdziak tucznokomórkowy – 37 chorych. Napromienianie przepro-
wadzono w warunkach telegammaterapii Co-60. Dawka ca∏kowita w badanej grupie wynosi∏a Êrednio 59,23 Gy i waha∏a si´
od 50 Gy do 64 Gy, frakcjonowana po 1,6-2,5 Gy raz dziennie. Stosowano nast´pujàce techniki radioterapii: trzy skrzy˝owa-
ne wiàzki (jedno pole przednie i dwa boczne z filtrami klinowymi) lub dwie wiàzki skrzy˝owane pod kàtem 90°, z u˝yciem fil-
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Introduction
Low grade astrocytomas account for 10-15% of primary
adult brain tumours [1-3]. The management of low-grade
cerebral astrocytoma is controversial. Surgery is usually
attempted and either biopsy or subtotal or total excision is
undertaken [4, 5]. Complete surgical resection is poten-
tially curative. After subtotaly resected tumour, different
polices are being pursued: planned immediate postopera-
tive radiotherapy [2, 6, 7] or retreatment by surgery or
radiotherapy on progression of the disease [8, 9]. Stereo-
tactic irradiation has been used more often in treatment
of low-grade gliomas [10].
At some institutions, nonresectable low-grade astro-
cytomas located in the brain stem are treated by intersti-
tial implants 125J or 192Ir [11]. Currently, there is no pro-
ven beneficial effect of chemotherapy in the treatment
of adult patient with newly diagnosed low-grade astrocy-
toma [12].
Materials and methods
119 patients with incompletely excised low-grade astrocytomas
(WHO grade II) [13] irradiated between 1976 and 1993 at the
Department of Radiation Oncology of Maria Sk∏odowska-Curie
Memorial Cancer Center in Kraków, were retrospectively re-
viewed. The parameters monitored to determine clinical re-
sponse to therapy included neurological function and perfor-
mance status (according to EORTC/MRC scale and Karnofsky
scale) [14, 15].
There were 61 female (51%) and 58 male (49%) patients
with a median age of 36 years (range: 15-68). Headache was
the most common presenting symptom in 80 cases (67%) at
pretreatment examination, followed by seizures in 68 cases
(57%), sensory or motor deficit in 50 cases (42%), nausea and
vomiting in 31 cases (26%) and disturbances of intellectual func-
tions or personality in 18 cases (15%). The distribution of sites of
involvement was as follows: frontal 49 patients (41%), temporal
46 patients (39%) and occipital 24 patients (20%). Tumour was
located in one lobe in 79 patients (66%), while in 40 patients
(39%) tumour extended beyond one lobe. All patients under-
went surgical resection aiming to remove as much tumoral tissue
as possible with preservation of neurologic function. 77 opera-
tions (65%) were considered as subtotal resections and 42 (35%)
as partial resections. The distribution of histologic types in the
study population was as follows: 60 fibrillary astrocytomas (50%),
22 protoplasmic astrocytomas (19%) and 37 as gemistocytic
astrocytomas (31%).
Before radiotherapy, performance status and neurologi-
cal function were assessed. Karnofski score was superior or equ-
al to 80% in 35 cases (30%), 70%-50% in 81 cases (68%) and
40% or less in 3 cases (2%). Neurologic function was assessed as
very good in 7 patients (6%), good in 77 patients (65%), mode-
rate in 32 patients (27%) and poor in 3 patients (2%)
All patients were treated with megavoltage gamma rays
(60Co). Radiotherapy was started one to five months (median 2
months) after surgery. The total dose ranged from 50 to 64 Gy
(mean: 59.23 Gy) delivered with daily fractions of 1.6-2.5 Gy.
The three-field technique (parallel-opposed lateral portals with
wedges and anterior portal), or anterior and lateral portals with
wedges were used. The treatment volume covered the tumour
residual with a margin of (1-2 cm). The techniques of radiothe-
rapy according to the total and fraction doses are given in Ta-
ble I.
Results
To l e r a n c e
The tolerance to treatment was assessed according to the
following criteria: very good – treatment without com-
plications, good – periodic symptoms of increased intra-
cranial pressure controlled pharmacologically with no
breaks in irradiation, poor – the above symptoms which
caused breaks in irradiation or its discontinuation. The
treatment was generally well tolerated. In 93 patients
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trów klinowych. Teren napromieniany obejmowa∏ pozosta∏oÊç guza z marginesem (1-2 cm). Oceniono wartoÊç prognostycz-
nà nast´pujàcych czynników: wiek, p∏eç, stan neurologiczny, stan sprawnoÊci, czas trwania i rodzaj objawów, lokalizacja gu-
za, zaawansowanie, utkanie mikroskopowe, doszcz´tnoÊç zabiegu, okres pomi´dzy operacjà a zabiegiem, dawka ca∏kowita.
W y n i k i. Tolerancja leczenia by∏a dobra. Odsetki prognozowanych prze˝yç 5- i 10-letnich wynosi∏y odpowiednio 39% i 24%.
W badanym materiale w analizie jednoczynnikowej wykazano prognostyczne znaczenie wieku chorych, p∏ci, stanu neurolo-
gicznego przed wdro˝eniem radioterapii oraz utkania mikroskopowego, wyró˝niajàcego gwiaêdziaka tucznokomórkowego.
W analizie wieloczynnikowej wiek najsilniej determinowa∏ rokowanie, najlepsze wyniki uzyskano w grupie chorych m∏odszych,
poni˝ej 30 roku ˝ycia.
W n i o s k i. 1. Skojarzone leczenie chirurgiczne z pooperacyjnym napromienianiem chorych na wysokozró˝nicowane gwiaê-
dziaki mózgu, po zabiegach nieradykalnych, pozwala na uzyskanie prognozowanych prze˝yç 5- i 10-letnich, wynoszàcych od-
powiednio 39% i 24%. 2. Tolerancja leczenia napromienianiem dawkà, wahajàcà si´ od 50 Gy do 64 Gy, frakcjonowanà kla-
sycznie, obejmujàcà pozosta∏oÊç guza z marginesem, jest dobra. 3. Wiek jest najsilniejszym czynnikiem prognostycznym
u chorych na wysokozró˝nicowane gwiaêdziaki mózgu, napromienianych po zabiegach nieradykalnych.
Key words: low-grade astrocytoma, radiotherapy, prognostic factors
S∏owa kluczowe: wyskozró˝nicowane gwiaêdziaki, radioterapia, czynniki prognostyczne
Tab. I. The techniques of radiotherapy according to total and fraction doses of 119 patients with low-grade astrocytomas
Techniques of radiotherapy Total dose Fraction dose No. of patients %
three-field technique 50-64 Gy 1.6-2 Gy 108 91
anterior and lateral portals 50-60 Gy 2-2.5 Gy 11 9
(78%) tolerance to treatment was assessed as very good,
in 25 patients as good. One patient had poor tolerance
and radiotherapy was discontinued after the dose 56 Gy in
28 daily fractions.
During radiotherapy, 29 patients (24%) showed im-
provement in neurological function, in 89 ones (75%)
neurological function was assessed as steady. In one case
neurological function became worse due to progression of
tumour.
S u r v i v a l
Length of survival was measured from the day of surgery.
The survival was estimated by Kaplan-Meier method [16].
Prognostics factor analysis included univariate and multi-
variate analysis. The Kaplan-Meier method and log rank
test were used for univariate analysis, the Cox regression
model was used for multivariate analysis [17, 18].
The overall actuarial survival rates at 5 and 10-years
were 39% and 24%, respectively (Fig. 1).
The following characteristics were associated with
improved patient survival by univariate analysis: age ≤30,
very good neurological function before radiotherapy, fi-
brillary or protoplasmic histology, female gender (test
log rank p≤0.05, Figs. 2-5). There was no difference in
survival in respect to Karnofsky performance status, type
and duration of symptoms, tumour location and volume,
extent of surgical resection, interval between the surgery
and radiotherapy, total dose. In Table II a univariate ana-
lysis of prognostic factors is presented. Multivariate ana-
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Tab. II. Univariate analysis of prognostic factors
Factors Relative risk p Actuarial p
10-year survival
Age
≤30 n=37 1.00 - 38% 0.0080
>30 n=82 1.85 0.0132 18%
Gender
female n=61 1.00 - 30% 0.0247
male n=58 1.62 0.0251 18%
Performance status
Karnofski ≥80 n=35 1.00 - 32% 0.0850
Karnofski <80 n=84 1.49 0.1032 20%
Neurological function
very good n=19 1.00 - 46% 0.0361
good.moderate.poor n=100 1.88 0.0605 20%
Symptoms
seizures n=68 1.00 - 24% 0.4256
others n=51 1.18 0.4264 22%
Length of symptoms
≥24 months n=36 1.00 - 19% 0.7585
<24 months n=83 0.93 0.7598 26%
Localisation
occipital n=24 1.00 - 33% 0.1342
frontal n=49 1.32 0.3571 23%
temporal n=46 1.71 0.0816 21%
Stage
one lobe n=79 1.00 - 25% 0.9873
more than one lobe n=40 1.00 0.9875 24%
Histology
a. fibr. & protop. n=82 1.00 - 30% 0.0359
a. gemistocyticum n=37 1.62 0.0309 13%
Surgery
subtotal resection* n=77 1.00 - 27% 0.5179
partial resection** n=42 1.15 0.5216 19%
Interval from operation to radiotherapy
≤month n=51 1.00 - 22% 0.3350
>month n=68 0.81 0.3568 23%
Total dose
≥6000 cGy n=100 1.00 - 25% 0.9245
<6000 cGy n=19 0.97 0.9265 18%
* subtotal resection: removal of the whole mass of tumour except that infiltrating deep brain structures
** partial resection: removal of only some parts of the tumour
lysis showed that only age was correlated with survival
time. Patients under 30 years of age carried the best pro-
gnosis. The definitive results of the Cox model are given
in Table III.
Re c u r r e n c e s
Clinical progression was observed in 81 patients (68%). In
70 cases it was documented by CT and in 11 cases asses-
sed only by neurological examination. Median time to
recurrence was 34 months (range: 1-97 months). 10 pa-
tients underwent second operation. Malignant transfor-
mation occurred in 7 patients, radiation necrosis was fo-
und in one case, and in two cases the tumour was histolo-
gically similar in appearance to the specimen removed
at the first operation.
Discussion
The 5-year overall survival of all 119 patients in this series
was 39%. This is worse, compared to survival rates re-
ported by other institutions, which ranges from 44-65%
(Table IV). Variability in the reported survival rates is li-
kely due to patients heterogeneity. In most series, pa-
tients with pilocytic astrocytoma, low-grade oligodendro-
glioma and oligoastrocytoma were included, which carried
better prognosis [1, 11, 19-23]. Some studies assessed
adults as well as children and supratentorial or infratento-
rial localisation [1, 19, 21, 24]. Present materials consisting
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Fig. 1. Overall actuarial survival of 119 irradiated patients with
incompletely excised low-grade astocytoma
Fig. 4. Overall actuarial survival of 119 irradiated patients with
incompletely excised low-grade cerebral astrocytoma according to
histology
Fig. 2. Overall actuarial survival of 119 irradiated patients with
incompletely excised low-grade cerebral astrocytoma according to age
Fig. 5. Overall actuarial survival of 119 irradiated patients with
incompletely excised low-grade cerebral astrocytoma according to gen-
der
Fig. 3. Overall actuarial survival of 119 irradiated patients with
incompletely excised low-grade cerebral astrocytoma according to
neurological function (EOTRC/MRC scale)
neur. function 1 – very good neurological function
neur. function 2, 3, 4 – good, moderate and poor neurological function
Tab. III. The definitive Cox model
Factor Relative risk P-value Confidence interval
Age 1.00 - -
≤30
>30 1.85 0.0132 1.14-3.02
of patients with known negative prognostic factors may
show relatively decreased survival.
Numerous prognostic factors have been reported
for low-grade astrocytomas such as age, sex, performance
status, neurological function, length and nature of symp-
toms, localisation, stage, histological subtype, proliferati-
ve potential of tumour, p53 mutations, markers of an-
giogenesis, CT contrast enhancement, extent of surgery,
postoperative radiotherapy – but no consensus has been
obtained [1, 19, 25-34].
Our results indicate that age is the principal variable
determining the survival times of patients with low-grade
astrocytomas. It was the only significant factor in multiva-
riate analysis. The actuarial 10 year survival rates were
18% and 38%, respectively, for patients at ages above 30
years and 30 years or less (p=0.008). Several other studies
had demonstrated better results in younger patients (the
cut-off point seems to lie somewhere between 20 and 45
years of age), and confirmed the importance of age in
treatment outcome [1, 21, 22, 24, 25, 30, 35-37]. In the se-
ries of 461 patients with supratentorial low-grade glio-
mas reported by Laws et al., 5- and 15-year survival rates
were, respectively, 83% and 71% for patients at the age of
20 years or less compared to 35% and 11% for patients in
age between 20 to 49 years (p<0.0002) [30]. An attempt
has been made to explain favourable prognosis in younger
patients by better tolerance of treatment: surgery as well
as radiotherapy.
The parameters of neurological status showed pro-
gnostic influence on survival in univariate analysis of our
series. Patients with very good neurological function befo-
re radiotherapy had better prognosis than others. The
actuarial 10-year survival rate was 46% for patients with
very good neurological function and 20% for patients
with good, moderate and poor neurological function
(p=0.0361). These findings agree with many other re-
ports [20, 33, 34, 38]. However, comparison of own results
with others is difficult due to differences of criteria used in
assessment of neurological status. Correlation between
neurological status and outcome indicates that treatment
should not be delayed until progression.
In our material, the Karnofsky performance status
did not significantly affect survival, similary to the results
of Janny's et al. series [26]. On the other hand, there are
a few reports, which point to the status performance as
one of the most significant prognostic factors [11, 21, 22,
24, 35, 37]. We observed that performance status was
a less important determinant of survival outcome than
neurological function. This is consistent with result of
randomised EORTC trial [38]. Assessment of status in
patient with brain tumour by the Karnofsky score or
WHO scale seems to be insufficient compared with neu-
rological status. Neurological status appears to be more
precise than performance status, which is assessed secon-
dary to neurological function.
In the current series, in univariate analysis, sex was
a statistically significant prognostic indicator, females fa-
red better than male patients (p=0.0247). Some authors
have also found gender to be a prognostic factor with
improved survival times in females, while other reports
have failed to find any significant impact of sex [1, 7, 21,
24, 26].
In the present study, patients with gemistocytic astro-
cytoma carried worse prognosis compared to patients
with fibrillary or protoplasmatic astrocytomas. The actu-
arial 10-year survival rates were 13% and 30% respective-
ly, for patients with gemistocytic astrocytoma and fibrilla-
ry or protoplasmic astrocytomas (p=0.0359). The gemi-
stocytic astrocytoma has been associated with poor
survival times in many others series, most likely due to the
high incidence of dedifferentiation and malignant trans-
formation [7, 19, 29]. In gemistocytic astrocytes, p53 mu-
tations and low expression of bcl-2 are more often obse-
rved [39].
In the presented series seizures had no influence on
prognosis. This is consistent with the study of Lote et al.
who found that epilepsy was not a significant prognostic
factor in patients with low-grade gliomas [40]. In con-
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Tab. IV. Results of postoperative radiotherapy of patients with low grade astrocytomas
Author No of patients Total dose Survival (%)
5-year 10-year
Leibel et al. 1975 71 35-50 Gy 46 35
[19]
North et al. 1990 66 50-55 Gy 55 43
[21]
McCormack et al. 1992 53 24-68 Gy 64 48
[20]
Shibamoto et al. 1993 101 41-66 Gy 60 41
[25]
Touboul et al. 1995 26 45-57.5 Gy 65 37
[11]
Bahary et al. 1996 43 50-60 Gy 67 -
[1]
Leighton et al. 1997 80 54 Gy 62 35
[24]
Rudoler et al. 1998 30 46.4-64 Gy 50 -
[33]
Present series 119 50-64 Gy 39 24
trast, North et al., Leighton et al. and Piepmier et al. re-
ported that seizures as a presenting symptom were asso-
ciated with better outcome [24, 34, 41]. Small tumours
may cause epilepsy years before any other symptoms, and
patients diagnosed with smaller tumours may be expected
to live longer.
Length of symptoms did not result in any differences
in survival (within the assessed range), similarly to other
studies [11, 20, 21, 24, 37]. Some authors observed length
of symptoms to have influence on outcome [23, 41]. Piep-
mer et al. found that patients presenting symptoms for
more than 2 years had a significantly longer time to recur-
rence (p=0.0001) and survival (p=0.0028) compared with
those with symptoms for less than 2 years [41].
Tumour localisation did not show a significant diffe-
rence in outcome. Pipemer et al. studying a series of 55
patients with low-grade astrocytoma, observed that tem-
poral lobe localisation was associated with significantly
longer time to recurrence (p=0.05), but they failed to
find significance for length of survival [41].
There were no differences between survival times
in patients with tumour limited to one lobe and patients
with tumour extended beyond one lobe. North et al. sho-
wed different results, patients with involvement of two
or more lobes fared significantly worse than patients with
involvement of only one lobe (p=0.016) [21]. According
to Berger et al. a strong correlation between size of tumor
and risk of recurrence and histological progression is ob-
served [4]. Staging classification assessing the number of
involved lobes seems to be imperfect, as it does not esti-
mate diameter of tumor, crossing the midline and encro-
aching on the ventricular system. Karim et al. in a rando-
mized trial, found that the „T” of the TNM classification
appears to be one of the most important prognostic fac-
tors (p<0.00001) on multivariate analysis. The T parame-
ter was significantly discriminant for prognosis of overall
survival (p<0.0001) as well as prognosis free survival
(p<0.0001) [38]. However, others did not find differences
in survival according to tumor size [7, 26, 32].
The usefulness of surgery in the management of low-
-grade astrocytomas remains disputable. Some authors
do not find advantage in removing them, whereas others
do and emphasise the relationship between the survival ti-
me and the extent of resection [1, 4, 7, 11, 21, 24, 25, 37,
42, 43]. The impact of the extent of surgery is difficult to
ascertain. Differentiation between gross total or subtotal
operation is subjective and conducted with high risk of er-
ror. The extend of resection assessed by surgeons very
often does not correlate with postoperative CT scans.
The majority of patients with low-grade gliomas die of
malignant transformation [31, 44]. About 13-85% of low-
-grade gliomas recur at a higher histologic grade [7, 9,
11, 21, 30]. Berger et al. suggest that the risk of recur-
rence is minimised when less residual tumour volume is
present after surgery [4]. In our series, patients who un-
derwent subtotal resection did not survive longer than
those in whom the tumor was partially removed. It should
be noted, however, that all operations were non-radical.
The interval from operation to radiotherapy (within
the assessed range) had no influence on survival time in
our series. The question whether to irradiate immediate-
ly after surgery or to delay treatment until progression, re-
mains unsolved. The optimal treatment and its time for
patients with low-grade gliomas is still controversial, but
all these opinions are based on the results from retro-
spective clinical studies [1, 7-9, 19, 24, 29, 36, 41, 44, 45].
No differences in survival were found in patients
who were treated with less than 60 Gy of radiation when
compared with those treated with 60 Gy or more. This fin-
ding is consistent with the result of prospective rando-
mised trial on dose-response in radiation therapy of low-
-grade cerebral glioma EORTC no 22844. For this study,
379 adult patients were included to receive irradiation
postoperatively or postbiopsy, with either 45 Gy in 5 we-
eks or 59.4 Gy in 6.6 weeks, with daily fractions of 1.8
Gy. There was no significant difference in terms of 5-
-year survival (58% for the low-dose arm and 59% for
the high-dose arm) or the 5-year progression free survival
(47% and 50%), between the two arms of the trial [38].
The absence of dose-response and time-response
may indicate that postoperative radiotherapy in patients
with low-grade astrocytomas is ineffective, but only pro-
spective study can assess the value of radiotherapy in this
group. Currently, two prospective randomised trials
(EORTC no 22845, RTOG no 9802) are in progress,
which have been designed to define the role of postopera-
tive radiation therapy for patients with supratentorial
low-grade gliomas and to characterise any dose-response
relationship.
Conclusion
1. Combined surgery and postoperative radiotherapy in
patients with incompletely excised low-grade cerebral
astrocytoma results in obtaining 5-year and 10-year
overall actuarial survival rates in 39% and 24% of ca-
ses, respectively.
2. The tolerance of radical radiotherapy with total do-
ses of 50-64 Gy delivered with classical factions, co-
vering the tumour residual with a margin, is good.
3. Age is the most significant variable determining the su-
rvival of patients with incompletely excised low-grade
astrocytoma. Patients under 30 years of age carried
the best prognosis.
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